Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Osimertinib Adjuvant (ADAURA) Four-Year Update
John reviews updated ADAURA data: three years of osimertinib, four-year DFS rates, follow-up differences, and pending OS analysis.
Play episode from 06:06
Transcript
